Replies to post #508518 on Anavex Life Sciences Corp (AVXL)

[Hosai]

For Blarca vs Donanemab:

Plasma NfL

Blarcamesine (approx, 48 w):
Placebo change ˜ +5 pg/mL
Drug change ˜ +1.5 pg/mL

Approx delta -3.5 pg/mL, so ~70% smaller rise (p = 0.28)

Donanemab (18 m):

Placebo change +19%
Drug change +15%

Delta -21% reduction (also not stat sig - no p value given).

Plasma Aß42/40

Blarcamesine (48w):
Placebo change = 0. Drug change = 0.013.
Delta vs placebo: +0.013 (p = 0.048)

Donanemab (18m):
Placebo up 2% from baseline - dosed up 4% from baseline (not stat sig - no p value given).

Arguably then for these two measures Blarca also beat Donanemab for 42/40 and directionally for Nf-l..

[frrol]

I did a similar biomarkers comparison myself months ago, found it too confusing with different scales and baselines to draw much insight.